Asphalion, a CataloniaBio & HealthTech member, has inaugurated new offices in Barcelona after 18 years working as a scientific and regulatory affairs consultancy firm. The company's new headquarters are at Carrer de Tarragona 151, right by the Sants train station.

"We're very happy with the change and aware that, now more than ever, we can provide more and better services for drug development and regulatory affairs to pharma, biotech and medical device companies," explains Lidia Cánovas, Asphalion general manager for Regulatory Affairs and member of the CataloniaBio & HealthTech board.

Asphalion also has offices in Madrid and Munich. The ...


Minoryx Therapeutics, CataloniaBio & HealthTech member, has created a fully owned subsidiary in Belgium. The new office, located in Brussels South Biopark (Charleroi) is due to launch operations this month.

The Belgian subsidiary will leverage the local biotech ecosystem to lead the research and development of MIN-102 in new orphan central nervous system (CNS) indications and will play an important role in the development of the company. 

Minoryx is recruiting several R&D positions for its Belgian site and headquarters in Tecnocampus Maresme-Mataró (Barcelona).

The company recently completed a €21,3 million Series B funding round led by the ...


Senolytic Therapeutics, a biotech company in the Life Biosciences group with offices in Boston and Barcelona, is the focus of a report in the Financial Times on how longevity and treatments for age-related illnesses are being promoted.

Life Biosciences was created in 2017 by David A. Sinclair, a professor in the Department of Genetics at Harvard Medical School, and the investor Tristan Edwards.

Senolytic develops novel classes of medicines that target and eliminate damaged cells (senescent). The researchers believe, and have proven in pre-clinical trials, that de-constructing these zombie cells will offset the adverse effects of ageing. The company ...


Institut Marquès, a CataloniaBio & HealthTech member, has launched a programme of scientific studies on semen quality in various countries, as nearly 17% of couples have sterility issues and the male partner is involved in more than 50% of these cases

The first study was conducted in Spain in 2004 and others have begun recently in Italy and Ireland.

After analysing semen samples from one thousand Spanish men, scientists saw that the factors commonly attributed to poor semen quality (stress, alcohol, etc.) are a myth and that the origin of the problem is chemical toxins. These substances, which take ...


AstraZeneca has announced organisational changes to support continued scientific innovation and commercial success in the main therapy areas as the company enters a new phase in its strategic development.

Included in the changes will be the arrival of the world-renowned oncology scientist, Josep Baselga. He was most recently Physician-in-Chief at Memorial Sloan Kettering Cancer Center. Prior to this, he was Associate Director at the Massachusetts General Hospital Cancer Center and Founding Director of the Vall d‘Hebron Institute of Oncology (VHIO) in Barcelona.

Currently, AstraZeneca is focused in three therapy areas: oncology; cardiovascular; renal, metabolism and respiratory. In Barcelona, the biopharmaceutical ...